Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26345588 | 0.84 | TTR (0.40) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL2040623 | 0.74 | VCAM1 (0.41) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL31038060 | 0.74 | TTR (0.64) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL3048555 | 0.74 | VCAM1 (0.41) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL11871037 | 0.74 | TTR (0.75) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL22664414 | 0.72 | TTR (0.48) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL21918828 | 0.72 | VCAM1 (0.39) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL11525607 | 0.72 | VCAM1 (0.39) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL3679283 | 0.72 | TTR (0.54) | TTRALBVCAM1MEN1KMT2A | |
| SCHEMBL3955231 | 0.72 | TTR (0.42) | TTRALBVCAM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10811622-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-10-20 | — | — | US | disclosed |
| WO-2020192042-A1 | ELECTROLUMINESCENT MATERIAL, METHOD FOR PREPARING ELECTROLUMINESCENT MATERIAL, AND LIGHT-EMITTING DEVICE | 武汉华星光电半导体显示技术有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-10693086-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10693086-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | TTR 2552/4885ALB 1141/4885VCAM1 2058/4885 |
| US-10811622-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | TTR 2552/4885ALB 1141/4885VCAM1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.